Atika Capital Management’s RAPT Therapeutics RAPT Stock Holding History

Atika Capital Management’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-94,245	Closed	-$3.19M	–	84
2025 Q4	$3.19M	Buy	+94,245	New	+$2.93M	0.34%	69
2022 Q1	–	Sell	-26,286	Closed	-$7.72M	–	101
2021 Q4	$7.72M	Buy	+26,286	New	+$7.03M	0.54%	66

Atika Capital Management's RAPT Position: Q1 2026 in Review

Atika Capital Management sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 94,245 shares — an estimated $3.19M sold.

Atika Capital Management first reported a position in RAPT in Q4 2021 and held it in 2 quarters. The position peaked at $7.72M in Q4 2021. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Atika Capital Management reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Atika Capital Management sold 94,245 RAPT Therapeutics shares in Q1 2026, an estimated $3.19M.
Atika Capital Management first reported a position in RAPT Therapeutics in Q4 2021 and held it in 2 quarters.
Atika Capital Management's RAPT Therapeutics position peaked at $7.72M in Q4 2021.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Atika Capital Management's 13F filing for Q1 2026, filed 14 May 2026.